Compare Commvault Systems Inc (CVLT) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs GSK plc — how do they compare? Commvault Systems Inc trades at $156 (market cap $6.25B), while GSK plc trades at $46.6 (market cap $91.88B). The key difference: GSK plc is far larger — about 14.7× Commvault Systems Inc's market cap, and GSK plc pays a 3.9% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and GSK plc for 93 Days on average.
| CVLT | GSK | |
|---|---|---|
Market Cap | $6.25B | $91.88B |
Volume | 632,727 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $176.52 | $61.18 |
52-Week Low | $75.18 | $43.24 |
Typical Hold Time | 17 Days | 93 Days |
Enterprise Value | $6.24B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $155.16, up 3.25% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $1.42 exceeding expectations, though valuation metrics remain elevated with a P/E of 96.73. Recent positive developments include AWS Data Competency achievement and expanded FedRAMP authorization, supporting the company's AI-focused resilience platform.
CVLT presents growth potential through its AI integration and cloud partnerships, but faces risks from high valuation multiples and declining profit margins. With 54.55% analyst buy ratings and a $156.55 consensus target, the stock appears fairly valued near current levels, requiring careful monitoring of execution against growth expectations.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
